the market?
Peregrine Pharmaceuticals
NASDAQ: PPHM
1.54
0.03
(1.99%)
| Today's Open | $1.56 |
|---|---|
| Previous Close | $1.51 |
| Daily Range | $1.51 - $1.59 |
| 52-Week Range | $0.42 - $5.50 |
| Market Cap | $211.2M |
| P/E Ratio | -5.21 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 1,339,125 |
| Average Daily Volume | 1,795,278 |
| Current FY EPS | -$0.23 |
How do you think PPHM
will perform against the market?
Top PPHM Bull/Bear Pitches
News & Commentary
Is Peregrine Preparing to Soar Again?
The company completes enrollment for a bavituximab breast cancer trial.3 Stocks That Blew the Market Away
These three companies posted better than expected results on the bottom line.February's Biggest Biotech Loser Bounces Back
Peregrine's roller coaster ride is as exciting for investors as it is nauseating.5 Reasons Not to Worry This Week
These five companies are posting year-over-year improvements on the bottom line.Peregrine Pharmaceuticals Earnings: An Early Look
Let's look forward to this company's next earnings report.These 3 Stocks Fell Like a House of Cards
These stocks just rolled over. Can they come back?Peregrine Investors: Once Bitten, Twice Shy
Investors aren't too excited about this secondary data analysis2 of These 3 Stocks Look Like Damaged Goods
These stocks just rolled over. Can they come back?Peregrine's Epic Failure (Maybe)
Peregrine Pharmaceuticals releases phase 2 data on bavituximab in pancreatic cancer without any p-values.Sector
Healthcare
Industry
Drugs
Peregrine Pharmaceuticals (PPHM) Description
A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases. Website: http://www.peregrineinc.com/
CEO Rating by Glassdoor
More details for Peregrine Pharmaceuticals Jobs
Peregrine Pharmaceuticals reviews from employees
